On Demand 2026 Sunday AM General Sessions

This course contains the following sessions from Sunday's Morning program:

  • Plenary: Immunodysregulation as the New Paradigm
  • 7 for 11: Hot Topics in Pediatrics A&I
  • Mast Cell Disease: Translating Current Evidence-Based Guidelines and Expert Consensus into Clinical Practice for the Allergist
  • Leveraging Technology to Reduce Disparities in Patient Care, Education, and Research
  • Introduction to Rhinolaryngoscopy

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Acknowledge the new paradigm that helps to explain the comorbidities in primary immunodeficiencies, and why the lines between immunology, rheumatology and hematology, along with other subspecialties are becoming increasingly blurred, necessitating a multidisciplinary approach to treating patients with inborn errors of immunity.
  • Critique the critical role of cytokines and chemokines in immune dysregulation and acknowledge how anomalies in cytokine function can disrupt normal immune homeostasis, leading to reversible or non-reversible changes that can lead to organ dysfunction and death and to understand the rationale behind treatment of cytokine driven inflammation.
  • Evaluate the development of new targeted therapies for immune dysregulation, the strategies for use of the respective agents in the face of varying etiologies and clinical presentations.
  • Summarize the use of biologics including monoclonal antibodies, fusion proteins, small molecule inhibitors, JAK-STAT pathway inhibitors or other immune modulators.
  • Compare new diagnosis and treatments for food allergy.
  • Identify updates in pediatric asthma and allergy.
  • Recognize changes in diagnosis and management of pediatric skin and immune disorders.
  • Differentiate between various types of mastocytosis and other non-clonal mast cell activation disorders focusing on diagnosis and clinical course.
  • Recognize clinical red flags that should trigger mast cell disease evaluation. Order and interpret tryptase testing, genotyping, urine mast cell mediators, and sensitive peripheral blood KIT mutation analysis.
  • Apply evidence-based guidelines and consensus criteria to distinguish SM, MCAS, and mimics in daily practice.
  • Develop an initial treatment algorithm for patients presenting with primary mast cell disorders, focusing on symptomatic management.
  • Develop enhanced anaphylaxis action plans for patients with mast cell disease. Implement perioperative risk reduction protocols through anesthesiology collaboration. Build effective multidisciplinary care pathways for complex patients.
  • Describe digital patient care tools, including telemedicine, physiologic monitoring, and remote therapeutic monitoring, that can reach patients who have access challenges.
  • Identify how digital tools, smartphone apps, and social media can provide evidence-based, reliable healthcare education to a broad patient network.
  • Compare benefits and barriers of novel digital methods for research study recruitment and virtual research study visits.
  • Describe the major anatomical findings in the upper airway.
  • Identify normal and abnormal anatomy, disease presentations and post-op findings.
  • Appraise indications for use of the rhinoscope in the allergist’s office.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary

Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Course opens: 
11/24/2026
Course expires: 
12/31/2027
Rating: 
0

S. Shahzad Mustafa, MD, FACAAI
Christopher Chang, MD, PhD, MBA, FACAAI
Sarah Emily Henrickson, MD, PhD
Hal M Hoffman, MD
Jordan S. Orange, MD, PhD, FACAAI
Travis A. Miller, MD, FACAAI
Todd A. Mahr, MD, FACAAI
Angela D. Hogan, MD, FACAAI
Theresa A. Bingemann, MD, FACAAI
J. Andrew A Bird, MD, FACAAI
Eric M. Schauberger, DO, PhD, FACAAI
Julie Wang, MD, FACAAI
Vivian P. Hernandez-Trujillo, MD, FACAAI
Ama Alexis, MD, FACAAI
Mariana C. Castells, MD, PhD, FACAAI
Mili Shum, MD, FACAAI
Cem Akin, MD, PhD, FACAAI
Jonathan Lyons, MD
Nathan A Boggs, MD, PhD
Matthew P. Giannetti, MD
Ruchi Shah, MD, FACAAI
Afia B. Adu-Gyamfi, MD
William C. Anderson, III, MD, FACAAI
Payel Gupta, MD, FACAAI, FAAAAI
Sakina S. Bajowala, MD
Jerald W. Koepke, MD, FACAAI
Seong H. Cho, MD, FACAAI

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Please login or create an account to take this course.